This work is licensed under the Creative Commons Attribution 4.0 International License.
Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39(Suppl 1): 7–18.KendallTVerheijJGaudioEEvertMGuidoMGoeppertBCarpinoGAnatomical, histomorphological and molecular classification of cholangiocarcinomaLiver Int201939Suppl 1718Search in Google Scholar
Bekki Y, Von Ahrens D, Takahashi H, Schwartz M, Gunasekaran G. Recurrent intrahepatic cholangiocarcinoma–review. Front Oncol. 2021; 11:776863. doi: 10.3389/fonc.2021.776863BekkiYVon AhrensDTakahashiHSchwartzMGunasekaranGRecurrent intrahepatic cholangiocarcinoma–reviewFront Oncol20211177686310.3389/fonc.2021.776863Open DOISearch in Google Scholar
Yang Z, Shi G. Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: a SEER population-based cohort study. Cancer Med. 2022; 11:692–704.YangZShiGSurvival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: a SEER population-based cohort studyCancer Med202211692704Search in Google Scholar
Cai C, Wang X, Fu Q, Chen A. The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2022; 20:40. doi: 10.1186/s12957-022-02511-7CaiCWangXFuQChenAThe VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysisWorld J Surg Oncol2022204010.1186/s12957-022-02511-7Open DOISearch in Google Scholar
Jin W. ErBb family proteins in cholangiocarcinoma and clinical implications. J Clin Med. 2020; 9:2255. doi: 10.3390/jcm9072255JinWErBb family proteins in cholangiocarcinoma and clinical implicationsJ Clin Med20209225510.3390/jcm9072255Open DOISearch in Google Scholar
Mancinelli R, Mammola CL, Sferra R, Pompili S, Vetuschi A, Pannarale L. Role of the angiogenic factors in cholangiocarcinoma. Appl Sci. 2019; 9:1393. doi: 10.3390/app9071393MancinelliRMammolaCLSferraRPompiliSVetuschiAPannaraleLRole of the angiogenic factors in cholangiocarcinomaAppl Sci20199139310.3390/app9071393Open DOISearch in Google Scholar
Ma Z, Li H, Liu L. Combining PD-1 inhibitor with VEGF/VEGFR2 inhibitor in chemotherapy: report of a patient with end-stage cholangiocarcinoma and review of literature. Recent Pat Anticancer Drug Discov. 2021; 16:101–7.MaZLiHLiuLCombining PD-1 inhibitor with VEGF/VEGFR2 inhibitor in chemotherapy: report of a patient with end-stage cholangiocarcinoma and review of literatureRecent Pat Anticancer Drug Discov2021161017Search in Google Scholar
Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, et al. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J Hepatol. 2019; 70:700–9.CadamuroMBrivioSMertensJVismaraMMoncsekAMilaniCPlatelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinomaJ Hepatol2019707009Search in Google Scholar
Liao W, Feng Q, Liu H, Du J, Chen X, Zeng Y. Circular RNAs in cholangiocarcinoma. Cancer Lett. 2022; 553:215980. doi: 10.1016/j.canlet.2022.215980LiaoWFengQLiuHDuJChenXZengYCircular RNAs in cholangiocarcinomaCancer Lett202255321598010.1016/j.canlet.2022.215980Open DOISearch in Google Scholar
Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review. Cancer Treat Res Commun. 2021; 27:100354. doi: 10.1016/j.ctarc.2021.100354RizzoABrandiGNeoadjuvant therapy for cholangiocarcinoma: a comprehensive literature reviewCancer Treat Res Commun20212710035410.1016/j.ctarc.2021.100354Open DOISearch in Google Scholar
Yoh T, Hatano E, Seo S, Okuda Y, Fuji H, Ikeno Y, et al. Long-term survival of recurrent intrahepatic cholangiocarcinoma: the impact and selection of repeat surgery. World J Surg. 2018; 42:1848–56.YohTHatanoESeoSOkudaYFujiHIkenoYLong-term survival of recurrent intrahepatic cholangiocarcinoma: the impact and selection of repeat surgeryWorld J Surg201842184856Search in Google Scholar
Moris D, Kostakis ID, Machairas N, Prodromidou A, Tsilimigras DI, Ravindra KV, et al. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: a systematic review and meta-analysis. PLoS One. 2019; 14:e0220527. doi: 10.1371/journal.pone.0220527MorisDKostakisIDMachairasNProdromidouATsilimigrasDIRavindraKVComparison between liver transplantation and resection for hilar cholangiocarcinoma: a systematic review and meta-analysisPLoS One201914e022052710.1371/journal.pone.0220527Open DOISearch in Google Scholar
Sarkis Y, Al Soueidy A, Kourie HR. Will advanced cholangiocarcinoma become a targetable malignancy? Crit Rev Oncol Hematol. 2021; 159:103233. doi: 10.1016/j.critrevonc.2021.103233SarkisYAl SoueidyAKourieHRWill advanced cholangiocarcinoma become a targetable malignancy?Crit Rev Oncol Hematol202115910323310.1016/j.critrevonc.2021.103233Open DOISearch in Google Scholar
Cai C, Wang X, Fu Q, Chen A. The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2022; 20:40. doi: 10.1186/s12957-022-02511-7CaiCWangXFuQChenAThe VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysisWorld J Surg Oncol2022204010.1186/s12957-022-02511-7Open DOISearch in Google Scholar
Song F, Hu B, Cheng JW, Sun YF, Zhou KQ, Wang PX, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020; 11:573. doi: 10.1038/s41419-020-02749-7SongFHuBChengJWSunYFZhouKQWangPXAnlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinomaCell Death Dis20201157310.1038/s41419-020-02749-7Open DOISearch in Google Scholar
Pan S, Hu Y, Hu M, Xu Y, Chen M, Du C, et al. S100A8 facilitates cholangiocarcinoma metastasis via upregulation of VEGF through TLR4/NFκB pathway activation. Int J Oncol. 2020; 56:101–12.PanSHuYHuMXuYChenMDuCS100A8 facilitates cholangiocarcinoma metastasis via upregulation of VEGF through TLR4/NFκB pathway activationInt J Oncol20205610112Search in Google Scholar
Takaya A, Yamamoto T, Tokoyoda K. Humoral immunity vs. Salmonella. Front Immunol. 2020; 10: 3155. doi: 10.3389/fimmu.2019.03155TakayaAYamamotoTTokoyodaKHumoral immunity vs. SalmonellaFront Immunol202010315510.3389/fimmu.2019.03155Open DOISearch in Google Scholar
Murakami T, Hiroshima Y, Miyake K, Kiyuna T, Endo I, Zhao M, Hoffman RM. Efficacy of tumor-targeting Salmonella typhimurium A1-R against malignancies in patient-derived orthotopic xenograft (PDOX) murine models. Cells. 2019; 8:599. doi: 10.3390/cells8060599MurakamiTHiroshimaYMiyakeKKiyunaTEndoIZhaoMHoffmanRMEfficacy of tumor-targeting Salmonella typhimurium A1-R against malignancies in patient-derived orthotopic xenograft (PDOX) murine modelsCells2019859910.3390/cells8060599Open DOISearch in Google Scholar
Zhao T, Guo M, Chen H, Zhou L, Guo J, Liu S, et al. IDO2-siRNA carried by Salmonella combined with nifuroxazide attenuates melanoma growth. Curr Mol Pharmacol. 2023; 16:881–93.ZhaoTGuoMChenHZhouLGuoJLiuSIDO2-siRNA carried by Salmonella combined with nifuroxazide attenuates melanoma growthCurr Mol Pharmacol20231688193Search in Google Scholar
Phan T, Nguyen VH, D’Alincourt MS, Manuel ER, Kaltcheva T, Tsai W, et al. Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. Cancer Gene Ther. 2020; 27: 235–45.PhanTNguyenVHD’AlincourtMSManuelERKaltchevaTTsaiWSalmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growthCancer Gene Ther20202723545Search in Google Scholar